RecruitingPhase IEN originalLeukemia

FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

This phase I trial tests the safety, side effects and best dose of FH-WT1-E50 TCR T cells with azacitidine for the treatment of minimal residual disease (MRD) positive acute myeloid leukemia (AML). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize WT1, a protein on the surface of cancer cells. These WT1-specific T cells may help the body's immune system identify and kill WT1 cancer cells. Azacitidine is in a class of medications called antimetabolites. It works by stopping or slowing the growth of cancer cells. Giving FH-WT1-E50 TCR T Cells with azacitidine may be safe and/or effective for the treatment of MRD positive AML.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Wiek 18 lat lub więcej
  • Potwierdzona diagnoza białaczki mieloblastycznej (nie APL)
  • Posiadanie określonego typu HLA (HLA-A*02:01)
  • Potwierdzenie białka WT1 w komórkach raka
  • Zdolność do zrozumienia i wyrażenia zgody na badanie
  • Kobiety i mężczyźni zdolni do prokreacji muszą używać antykoncepcji przez co najmniej 4 miesiące po leczeniu
  • Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu
  • Niezaplanowany przeszczep szpiku w ciągu 8 tygodni

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 17, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (1)

Fred Hutch/University of Washington Cancer Consortium

Seattle, United States

Trial contact

Fred Hutch Immunotherapy Intake

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/18/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.